

April 30, 2021

News Release

Company: Olympus Corporation
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

(Change of Disclosure Matters)

**Notice Regarding start of the process to acquire Israeli medical device company Medi-Tate Ltd.
(new subsidiary) pursuant to its call option rights**

Olympus Corporation ("Olympus") hereby announces the change of the closing date to acquire all of the outstanding shares of Medi-Tate Ltd. ("Medi-Tate"), a medical device company registered in Israel. The acquisition was originally announced in the timely disclosure "Notice Regarding start of the process to acquire Israeli medical device company Medi-Tate Ltd. (new subsidiary) pursuant to its call option rights" dated February 26, 2021.

1. Reasons for acquiring shares

Olympus exercised its call option right to acquire all of the outstanding shares of Medi-Tate on February 26, 2021, and the definitive agreement to acquire the shares was scheduled to be executed on March 31, 2021. However, as a result of careful confirmation and procedures by all parties concerned regarding the definitive agreement, the contract was signed later than scheduled and was completed on April 30, 2021 (Central European Time). Due to the delay in the conclusion of the contract, the scheduled date of share acquisition has been changed.

There is no change in the transfer price and other conditions.

2. Schedule

	Before revision	After revision
Date of signing	On March 31, 2021 (planned)	On April 30, 2021
Date of closing	On April 30, 2021 (planned)	On May 31, 2021 (planned)

3. Future Outlook

Olympus does not believe that there will be a material impact on the financial results for the year ending March 31, 2022. Olympus will promptly provide notice as soon as additional items to be disclosed have arisen.